Neurology
RSSArticles
-
Ombitasvir, Paritaprevir, and Ritonavir, Dasabuvir Tablets (Viekira™ Pak)
The FDA has approved the fourth new product for the treatment of chronic hepatitis C (HCV) infection since November 2013. The latest is a four fixed-drug combination (3-DAA) that includes paritaprevir, a nonstructure 3/4A protease inhibitor, ombitasvir, an inhibitor of the NS5A replication complex, and copackaged with dasabuvir, a nonnucleoside NS5B polymerase inhibitor. The plasma levels of paritaprevir is boosted with ritonavir, a CYP3A inhibitor to permit once-daily dosing. The combination is marketed by AbbVie, Inc. as Viekira Pak.
-
Can Intracardiac Echo Be Used as a Substitute for Transesophageal Echo Prior to Atrial Fibrillation Ablation?
This article originally appeared in the January 2015 issue of Clinical Cardiology Alert.
-
Should Metformin Use In Patients With Chronic Kidney Disease Be Expanded?
SYNOPSIS: Expansion of the metformin label to include patients with mild-to-moderate kidney disease is appropriate.
-
Nonsteroidal Anti-inflammatory Drug Use and Risk of Atrial Fibrillation
SYNOPSIS: Use of nonaspirin nonsteroidal anti-inflammatory drugs (NSAIDs) was associated with an increased risk of incident atrial fibrillation, especially among new users of NSAIDs.
-
Paradoxical Low-flow, Low-gradient AS
This article originally appeared in the January 2015 issue of Clinical Cardiology Alert. It was peer reviewed by Susan Zhao, MD. Dr. Crawford is Professor of Medicine, Chief of Clinical Cardiology, University of California, San Francisco. He is the editor of Clinical Cardiology Alert. Dr. Zhao is Director, Adult Echocardiography Laboratory, Associate Chief, Division of Cardiology, Department of Medicine, Santa Clara Valley Medical Center. Dr. Crawford and Dr. Zhao report no financial relationships relevant to this field of study.
-
Sudden Death Risk: ARBs or ACE Inhibitors & Co-trimoxazole
Older patients using an angiotensin-converting enzyme inhibitor or an angiotensin receptor blocker with co-trimoxazole had an increased risk of sudden death.
-
Prior Authorization versus Prospective Audit with Provider Feedback: Does the Effectiveness of the Core Antimicrobial Stewardship Strategies Differ?
SYNOPSIS: In a single academic medical center, changing from a strategy of prior authorization to prospective audit with feedback led to significantly increased total antibiotic use and use of agents with a broad spectrum of gram-negative activity.
-
Should Long-acting Bronchodilators Be Used in Acute Exacerbations of COPD?
ABSTRACT & COMMENTARY: There's a disappointingly high rate of non-recommended drug administration.
-
Clinical Briefs
Topics: Metformin: Have we Been Overcautious in CKD?, Reduction in Prostate, and Doing the Right Thing for Acute Bronchitis in Healthy Adults: Antibiotics
-
Edoxaban Tablets (Savaysa™)
The third oral factor Xa inhibitor has been approved by the FDA. Edoxaban is the fourth target-specific oral anticoagulant (TSOA) to enter the market following dabigatran (Pradaxa), rivaroxaban (Xarelto), and apixaban (Eliquis). Edoxaban is manufactured by Tokyo-based Daiichi Sankyo Company and marketed by Daiichi Sankyo as Savaysa.